Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by ChiefBroncoon Mar 20, 2020 10:18am

72 Views

Post# 30830128

RE:Stero/bassada and his friends want to takeover kly BECAUSE

edrose wrote: We are worth at least .30 like echelon stated

We we have great phase 2 results and our product will be approved after phase3 that takes only one year

WE DONT EVEN WANT US TO SEE STERO STUDY RESULTS. WHY? Are they bad are they statistically insignificant and not worth anything

No it's the opposite they dont want investors to see value as it would bring sp up, but they have a load of shares to buy and there greedy and want the cheapest shares as posible even if it means hurting some retail investers. Once there done buying shares you will see sp go up I guarantee it.

Bullboard Posts

The top 10 Canadian medical stocks